Lisa Flaum

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer

Young Kwang Chae, Andrew A. Davis, Sarika Jain et al. · Molecular Cancer Therapeutics · 2017 · 141 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

Ingrid A. Mayer, Fengmin Zhao, Carlos L. Arteaga et al. · Journal of Clinical Oncology · 2021 · 136 citations · Full text

Medicine, Oncology, Pharmacology +17

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer

Cesar August Santa-Maria, Taigo Kato, Jae‐Hyun Park et al. · Oncotarget · 2018 · 133 citations · Full text

Medicine, Immunology, Oncology +17

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

Ami N. Shah, Lisa Flaum, Irene Helenowski et al. · Journal for ImmunoTherapy of Cancer · 2020 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17